| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |